Sign in

    Kyle Rose • Piper Sandler

    Kyle Rose's questions to Neuronetics Inc (STIM) leadership

    Kyle Rose's questions to Neuronetics Inc (STIM) leadership • Q3 2024

    Question

    Kyle Rose of Piper Sandler inquired about the reasons for the 2024 full-year guidance reduction and its implications for 2025. He also asked if Neuronetics remains committed to its mid-teens growth target for the combined entity in 2025 and 2026.

    Answer

    CFO Stephen Furlong explained the guidance reduction stems from changing customer purchasing patterns due to earlier reimbursement issues, leading to historically low inventory levels. He noted that while system utilization remains strong, the recent commercial restructuring to prioritize profitability will impact Q4 revenue. Furlong stated that the primary focus is now on achieving cash flow breakeven by Q3 2025, which may come at the expense of top-line growth, making the previous mid-teens growth target a secondary goal.

    Ask Fintool Equity Research AI

    Kyle Rose's questions to Dexcom Inc (DXCM) leadership

    Kyle Rose's questions to Dexcom Inc (DXCM) leadership • Q3 2024

    Question

    Kyle Rose asked for qualitative commentary on the patient mix between Type 1 and Type 2 diabetes within the record new patient starts.

    Answer

    CFO Jereme Sylvain clarified that the record new patient starts exclude Stelo. He described the growth as 'broad-based across the insulin-using population,' with robust adoption in all categories. While intensive insulin users (both T1 and T2) continue to lead, he noted that the basal insulin segment also remains strong.

    Ask Fintool Equity Research AI